LinkMed intensifies activities - prepares exits

Press release
January 15, 2008

LinkMed intensifies activities - prepares exits

Several of LinkMed's portfolio companies are entering into a more mature phase.
Subsequently, LinkMed is intensifying exit preparations. In order to manage a
higher tempo, the organization is strengthened with two key employees: Agneta
Edberg and Jonas Graff-Lonnevig.

“By 2010, LinkMed will have carried out a couple of exits. We are therefore
delighted to be able to strengthen our team with Agneta and Jonas. We will now
be able to step up tempo in our portfolio companies, while at the same time
preparing for exits,” says CEO Ingemar Lagerlöf.

Current LinkMed AB board member Agneta Edberg is taking on the position as COO
and Senior Venture Manager, with operational responsibility for portfolio
company development, among other tasks. Agneta Edberg has held a number of
leading positions in both large and smaller life science companies and
organizations, most recently as Vice President in Bactiguard AB. Agneta Edberg
will leave the LinkMed Board of Directors in conjunction with taking on her new
position. 

Jonas Graff-Lonnevig was recruited to the new position of VP Financial
Transactions, and will focus on exit activities. Jonas has extensive experience
in business transactions and joins LinkMed from Arctos M & A, one of Sweden's
leading financial advisors in cross-border transactions in the mid-size company
sector, where he was partner. 

Adding two new companies to the portfolio in 2007, LinkMed's portfolio now
consists of a total of 12 companies within medical technology, biotechnology and
drug development. Activity in all portfolio companies increased last year, with
a number of companies launching new products and reaching key development
milestones. 


For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed	 +46 (08) 508 939 93


LinkMed develops new life-science companies in collaboration with innovators. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, six in drug development and biotechnology and six in medical
technology. The LinkMed share is listed on the OMX Nordic Exchange, Stockholm,
and the company's largest shareholders are FastPartner, Koncentra Holding, and
the founder Ingemar Lagerlöf. See www.linkmed.se for more information.